Introduction: approximately eighty million people around the world are living with hepatitis C, and 700,000 people die every year, due to hepatitis C related complications. In Seychelles, a total of 777 cases of hepatitis C were reported from 2002 to 2016, but up to mid of 2016, the cases were not being treated. Treatment with Harvoni, a combination of sofosbuvir and ledipasvir (SOF/LDV), is now being offered on the condition that the patient does not, or has stopped, injecting drugs. This paper is the first to establish the cost effectiveness of treating all cases of hepatiti s C in Seychelles with Harvoni, as compared to no treatment. Methods: data extracted from literature was used to populate an economic model to calculate cost-effectiveness from Seychelles' government perspective. The model structure was also informed by the systematic review and an accompanying grading of economic models using the Consolidated Health Economic Evaluation Reporting Standard (CHEERS) checklist. A Markov model was developed, employing a lifetime horizon and costs and benefits were analysed from a payer's perspective and combined into incremental cost effectiveness ratios (ICERs). Results: the direct-acting antiviral (DAA), Harvoni, was found to be cost-saving in Seychelles hepatitis C virus (HCV) cohort, as compared to no treatment, with an ICER of € 753.65/QALY. The treatment was also cost-saving when stratified by gender, with the ICER of male and female being € 783.74/QALY and € 635.20/QALY, respectively. Moreover, the results obtained from acceptability curves showed that treating patients with Harvoni is the most cost-effective option, even for low thresholds. Conclusion: treating hepatitis C cases in Seychelles is costsaving. It is worth developing a treatment programme to include all cases of hepatitis C, regardless of status of drug injection.
Introduction
The World Health Organization estimates that over 80 million people worldwide are living with chronic infection of hepatitis C (HCV), with a global prevalence of 1.1% [1] . Every year, more than 700,000 deaths occur due to complications related to hepatitis C, such as liver cirrhosis, liver failure and hepatocellular carcinoma [1] . Up to 2014, the mainstay of hepatitis C treatment in high income countries was weekly PEGylated interferon for 24-28 weeks, along with ribavirin for about six months [1] . The cure rates were less than 50%, the regimen was expensive, and there were significant side effects, such as headaches, muscle aches and fever [1] . The first all oral HCV treatment, direct-acting antivirals (DAAs), were approved by the European commission in January 2014 [2] . The side effects of DAAs are minimal, and the cure rates are more than 90% after 12 weeks of treatment, regardless of co-morbidities or stage of disease of the patient [1] . Several countries have now updated their treatment programmes [1] . Despite this revolution in the treatment, hepatitis C elimination still faces several barriers. Firstly, the cost of the DAAs are high for both individuals and health systems [1] . Secondly, the access to treatment is lower than ideal for those who are known to be at higher risk of getting infected, such as people who inject drugs (PWID) [3] . PWID are a high-risk group due to the transmission of hepatitis C virus through sharing of needles during drug use [4] . DAAs are now recognised as the recommended treatment for hepatitis C worldwide [5] . The World Health Organization (WHO) has released updated screening and treatment guidelines to assist countries in making decisions while developing their treatment protocols [5] . In May 2016, the World Health Assembly (WHA) adopted a strategy to reduce hepatitis C incidence by 90% and reduce mortality by 65% by 2030 [6] . To achieve these targets, prevention and treatment programmes will have to be scaled up [1, 6] . In the context of treatment, the requirement is to place 80% of patients with chronic hepatitis C on treatment [1, 6] . However, the barriers, as mentioned earlier, need to be addressed.
Seychelles is a group of islands in the Indian Ocean, just off the east coast of mainland Africa. It had a total estimated population of 94,205 at the end of 2016, the smallest of any African nation [7] . The country has universal healthcare that is publicly funded for all citizens [8] .
Under the umbrella of the Public Health Agency (PHA), the Communicable Disease Control Unit (CDCU) is the only Specialist Referral Centre (SRC) in Seychelles for management of communicable diseases, including hepatitis C [8] . The first positive diagnostic test result for hepatitis C in Seychelles was in 2002 [9] . Between 2002 and 2016, a total of 777 cases were reported, of which 648 cases (83%) were males and 129 cases (17%) were females [9] . The key population group most at risk are people who inject drugs (PWID), making up 99% of the hepatitis C cases recorded [9] . Furthermore, 16% were co-infected with both hepatitis C and HIV [9] . In this same time frame, there were 26 (3%) hepatitis C related deaths, of which 16 were males and 10 were females [9] . Figure 1 shows the increasing trend in hepatitis C incidence in Seychelles, from 2008 to 2016. The DAA Harvoni was introduced into the hepatitis C treatment options as of June 2016 [10] . Thirty patients have initiated treatment with it in the first year [10] . Harvoni is a combination of sofosbuvir and ledipasvir (SOF/LDV), produced by Gilead Sciences [1] . It is now the recommended treatment for HCV infection with genotypes 1, 4, 5 and 6 [1, 5] . Seychelles has access to Harvoni, at the cost of $800 for 8 weeks course, and $1200 for 12 weeks course, for each patient [10] . The current recommended duration of treatment for Harvoni is 12 weeks, regardless of viral load [5] . Treatment provision in Seychelles is prioritised for those who have stopped, injecting drugs [10] . Persons still injecting drugs continue to have limited access to treatment for hepatitis C [10] . Their high risk of re-infection together with the high cost of the current treatment plays a major role here [10] . We aimed to evaluate the cost effectiveness of treating all the hepatitis C cases in the Seychelles population, in comparison to not treating these cases.
Methods
A systematic review was carried out, using MEDLINE (Ovid), Embase (Ovid) and University of York Centre for Reviews and Dissemination, and data was extracted from the 21 identified studies. Transition probabilities and utility values used were extracted from literature.
The EuroQol 5 dimensions questionnaire was used to report utilities.
Evidence from the systematic review was used to populate an economic model to calculate cost-effectiveness from Seychelles' Government perspective. The model structure was also informed by the systematic review and an accompanying grading of economic models using the Consolidated Health Economic Evaluation Reporting and a control cohort (no Rx cohort), of 1000 HCV patients each, were followed through the Markov model for a duration of 60 years. The cohort was representative of the Seychelles cohort of patients infected with hepatitis C by the end of 2016, with the mean age of the patients being 32 years, 84% being male and 16% being female [11] .
Results
Base case analysis: the results showed that treating HCV patients with Harvoni (SOF/LDV) was cost-saving as compared to no treatment. This is presented in Table 1 Table 2 below. Furthermore, the cost gap between the two treatment options is raised from € 12,676,396.21 to € 25,167,920.84.
However, these results are presented here for comparison sake only. Table 3 and Table 4 below show results for male and female subgroups, respectively. The difference in results of the two subgroups were driven by the gender differences in general mortality rate. Stratification by gender results in the same conclusion of treatment with Harvoni being cost saving, as compared to the no treatment option, with negative ICER results for both subgroups.
However, the results show that it is more cost-saving to treat male patients than it is to treat female patients, reflected in the lower ICER for male group than for female group. This may be explained by the lower life expectancy in males for all age-groups.
Sensitivity analysis: due to the lack of primary data from Seychelles, there is likely to be considerable uncertainty around the ICER estimates. This uncertainty is addressed in probabilistic sensitivity analysis (PSA) by varying input parameters according to a distribution, as shown in Table 5 . The parameters used in this study were distributed. Transition probabilities and utility values ranged from 0 to 1, and so beta (β) distribution was used to determine their distribution. For the determination of distribution of costs, a gamma (γ) distribution was used. A simulation using 1000 trials was conducted in excel for the probabilistic sensitivity analysis (PSA). The PSA results can be presented on a cost-effectiveness plane, as shown in Figure 3 . The X axis (horizontal axis) measures the incremental effect and the Y axis (vertical axis) measures the incremental costs.
The north-west quadrant represents a situation whereby the new treatment is both, costlier and less effective, rendering it dominated by no treatment. The south-east quadrant represents a situation whereby the new treatment is more effective, being less costly and more effective than not treating hepatitis C. The north east and south west quadrants are less straightforward, showing a costlier and more effective, or a less costly but less effective situation, respectively. In these two situations, cost-effectiveness is decided according to whether the ICER is above the willingness to pay threshold. Figure   3 shows that in most of the simulations, the estimated ICER falls into the south-east quadrant. Hence, the new treatment with Harvoni is more effective and less costly than 'no treatment' option. Most of the uncertainty seems to come from the costs, given that the spread of data points is wider for costs (vertically) than for QALYs (horizontally). Figure 4 shows the cost-effectiveness acceptability curve (CEAC) depicting the percentage of the simulation that were cost-effective for Harvoni (Neuromuscular blockade (NMB) treatment), and for no treatment option (NMB treatment), at different willingness to pay thresholds. The different willingness to pay threshold presented are approximately one, two, three, and four times the GDP per capita of Seychelles in Euro, shown as 13000, 26000, 39000, 52000, and 65000, respectively. According to the CEAC, even at a lower WTP, there is still a high probability (>97%) that treatment will be cost-effective, compared with 'no treatment'. Only direct medical costs were considered, disregarding societal costs and consequences. This may have led to undervaluation of the treatment, and its ability to decrease travel costs to health centres, and increase work production. Furthermore, the lack of a similar study in a comparable country to Seychelles, in terms of population size, patient profiles, health care system construct, and income per capita, makes it a challenge to validate the results. Seychelles is currently prioritising patients who are at low risk of re-infection for enrolment into the treatment programme [10] . Accessibility to treatment for those who are at higher risk of spreading the infection, such as people who currently inject drugs and prisoners, remain a challenge. The secondary data of HCV patients in Seychelles revealed that 90% were People who inject drugs (PWID) and 25% were diagnosed while serving a prison sentence [11] . Screening with subsequent treatment of high risk patient groups need to be encouraged to slow down further transmission rate and decrease incidence. Hopefully, these results will motivate the extension of treatment programme to target more PWID and prisoners as well. The cost of DAAs remain one of the main barriers of HCV treatment. Even if it has been proven that treatment is cost-effective, the initial cost of treatment is still high, particularly for a developing country. The results of this research show how the treatment is not only cost-effective, but cost saving.
Treatment is an investment, from which benefits will be acquired decades later. It is, therefore, tactical to find ways to treat HCV before the complications set in. One way to dilute the high initial cost of treatment can be to spread it out over years. One proposed way of reducing the risk of infection in PWID is to use the 'treat your friends' approach, proposed by Hellard et al [3] . The theory behind this is that most PWID only share needles with a small group of other injectors whom they trust [3] . Using this approach of treating the whole cluster of injectors at one time reduces risk of reinfection, as their risk is highly reliant on the HCV status of the people they share needles with [3] .
Conclusion
In conclusion, the findings of this study demonstrate that treatment of hepatitis C cases in Seychelles is cost-saving as opposed to no treatment. Additionally, it makes the WHO's goal to eliminate hepatitis C as a public health burden by 2030 an achievable one for Seychelles.
These results make a strong case for expansion of the treatment programme in Seychelles to benefit all HCV patients, regardless of status of drug injection. Accompanying efficient prevention programmes, and an expended screening programme, the treatment has the ability to decrease HCV incidence. 
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